Protein glycosylation is a heterogeneous post-translational modification (Ptm) that plays an essential role in biological regulation. however, the diversity found in glycoproteins has undermined efforts to describe the intact glycoproteome via mass spectrometry (ms). We present isotaG, a mass-independent chemical glycoproteomics platform for characterization of intact, metabolically labeled glycopeptides at the whole-proteome scale. in isotaG, metabolic labeling of the glycoproteome is combined with (i) chemical enrichment and isotopic recoding of glycopeptides to select peptides for targeted glycoproteomics using directed ms and (ii) mass-independent assignment of intact glycopeptides. We structurally assigned 32 n-glycopeptides and over 500 intact and fully elaborated o-glycopeptides from 250 proteins across three human cancer cell lines and also discovered unexpected peptide sequence polymorphisms (psPs). the isotaG platform is broadly applicable to the discovery of Ptm sites that are amenable to chemical labeling, as well as previously unknown protein isoforms including psPs.
Protein glycosylation is a heterogeneous post-translational modification (Ptm) that plays an essential role in biological regulation. however, the diversity found in glycoproteins has undermined efforts to describe the intact glycoproteome via mass spectrometry (ms). We present isotaG, a mass-independent chemical glycoproteomics platform for characterization of intact, metabolically labeled glycopeptides at the whole-proteome scale. in isotaG, metabolic labeling of the glycoproteome is combined with (i) chemical enrichment and isotopic recoding of glycopeptides to select peptides for targeted glycoproteomics using directed ms and (ii) mass-independent assignment of intact glycopeptides. We structurally assigned 32 n-glycopeptides and over 500 intact and fully elaborated o-glycopeptides from 250 proteins across three human cancer cell lines and also discovered unexpected peptide sequence polymorphisms (psPs). the isotaG platform is broadly applicable to the discovery of Ptm sites that are amenable to chemical labeling, as well as previously unknown protein isoforms including psPs.
Glycosylation of proteins generates greater proteomic diversity than any other PTM. In eukaryotes, most glycans are attached to proteins at asparagine (N-glycans) or serine or threonine (O-glycans) side chains. These forms of glycosylation regulate a range of biological processes, including protein folding and trafficking 1 , signaling 2 and cell-cell communication 3 . Dynamic changes in protein glycosylation have been found to accompany disease states such as Alzheimer's 4 and cancer progression 5 , suggesting that specific protein glycoforms 6 , and the enzymes that generate them 7 , may serve as disease biomarkers and therapeutic targets.
Methods to profile the intact glycoproteome would enable correlation of glycosylation variants with disease state, yet structural characterization of glycoproteins poses a great challenge in biology 8, 9 . MS is often the method of choice for profiling the proteome, but expansion of MS methods for profiling the glycoproteome is uniquely problematic. In contrast to proteomic profiling of uniform PTMs (such as phosphorylation 10, 11 and acetylation 12 ), intact-glycopeptide analysis faces challenges on two fronts: detection by MS and computational identification via database searching. Glycan heterogeneity produces a number of substoichiometric modifications to the glycopeptide that effectively reduce the quantity of any particular glycoform. Because of this, as well as the lower ionization efficiency of glycoconjugates 13 , the detection of intact glycopeptides often requires increased sample quantities and enrichment. Moreover, the heterogeneity and nontemplated nature of glycopeptides stymie computational analysis. Crucially, most high-throughput proteomic platforms rely on database searches for peptide identification 14 . Nontemplated PTMs (for example, glycosylation) present significant computational challenges on the proteome level. Whereas a consensus sequence exists for N-glycosylation (N-X-S/T, where X is not proline), there are no defined consensus motifs for the various types of O-glycosylation. Indeed, the sheer number of possible glycoforms associated with the entire proteome yields an unmanageable sum of combinations for database search algorithms to match.
Without a universal method to identify glycoforms by database searches, enrichment of specific glycoprotein subtypes and reduction of glycan heterogeneity are presently required for glycoproteomic profiling. Enrichment of specific glycoprotein subtypes has been achieved via metabolic labeling [15] [16] [17] [18] , chemical tagging 19, 20 , enzymatic labeling 21 and lectin chromatography [22] [23] [24] . Nonetheless, identification of glycopeptides from whole proteomes requires reduction of the glycans to a uniform and predictable mass. Reduction of the glycan has been achieved for N-glycoproteins by enzymatic digestion (by PNGase F and EndoH) 25 and for O-glycans by genetic engineering (SimpleCell) 26, 27 . However, truncation of the glycan destroys information correlating glycan structural heterogeneity to the protein attachment site and undermines further correlation with biological activity. Methods for broadly profiling intact glycopeptides on the wholeproteome scale have until now remained elusive.
Here we present a mass-independent chemical glycoproteomics platform that enabled us to identify hundreds of intact glycopeptides from whole cell glycoproteomes. The platform, termed isotope-targeted glycoproteomics (IsoTaG), comprises four central components: (i) metabolic labeling with a chemically functionalized glycan, (ii) chemical tagging and enrichment using an isotopic recoding affinity probe, (iii) directed tandem MS and (iv) targeted glycopeptide assignment. In earlier work, we developed a computational algorithm, termed isotopic signature transfer and mass pattern prediction (IsoStamp) 28 , for the detection of recoded species in full-scan mass spectra. Here, we show that an IsoTaG approach improved glycopeptide targeting and led to the identification of 32 intact N-glycopeptides and over 500 intact O-glycopeptides from 250 glycoproteins across three cancer cell lines. Approximately 50% of the identified proteins were not previously known to be glycosylated. Furthermore, the specific peptide sequences for 60% of the glycopeptides were assigned as glycosylated for the first time.
results design and implementation of the isotaG platform
Critical to the performance of IsoTaG is the design and synthesis of dibrominated biotin tag 1 that allows for click chemistry-based affinity enrichment, recovery of the glycopeptide, and isotopic recoding of the intact glycopeptide (Fig. 1, Supplementary Fig. 1 and Supplementary Methods). Several cleavable linkers have been developed for proteomics applications; 29 we selected the silane scaffold 30 because of our observation that glycosidic linkages tolerate its mild acid cleavage conditions (2% formic acid in H 2 O). The natural abundance of the stable isotopes, 79 Br and 81 Br (1:1), provided a ready source for isotope recoding. In previous work we found that the dibromide motif, which convolutes the mass envelope of a peptide with a triplet signature (1:2:1 (M, M + 2, M + 4)), could be detected computationally using a pattern-recognition algorithm that we developed in-house 28 .
We tested probe 1 in a glycoproteomics analysis of Jurkat cell lysates using the IsoTaG workflow (Fig. 2a) . To demonstrate the flexibility of the platform for various glycoprotein subtypes, we labeled Jurkat cells separately with tetraacetylated N-azidoacetylgalactosamine (Ac 4 GalNAz), tetraacetylated N-azidoacetylmannosamine (Ac 4 ManNAz) or dimethylsulfoxide (DMSO) vehicle for 48 h. Ac 4 ManNAz is metabolized to the corresponding N-azidoacetyl sialic acid (SiaNAz) to yield labeled sialoglycoproteins 31 . Ac 4 GalNAz is processed by the cellular GalNAc salvage pathway to form UDP-GalNAz, which is interconverted by the UDP-galactose 4-epimerase (GALE) with its C4 epimer, UDP-GlcNAz 15 . Thus, metabolic labeling with Ac 4 GalNAz produces GalNAz-labeled mucin-type O-glycoproteins, GlcNAz-labeled N-glycoproteins and O-GlcNAzylated proteins. We harvested labeled Jurkat cells by centrifugation and collected the media by centrifugal filtration for analysis of secreted glycoproteins. In addition, the cell pellet was homogenized and separated into soluble and insoluble fractions. Three milligrams of protein per fraction were used as a starting point for glycoproteomics enrichment.
Fractionated Jurkat cell lysates were conjugated to probe 1 via copper-catalyzed azide-alkyne [3+2] cycloaddition (CuAAC; Fig. 2a) . Excess probe was removed by methanol precipitation, and proteins were resuspended in 1% RapiGest surfactant in PBS. Glycoproteins were enriched by streptavidin-agarose affinity chromatography and digested on-bead with trypsin to release all nonconjugated peptides for glycoprotein identification. Treatment with 2% formic acid recovered the glycopeptides from the beads. The efficiency of glycoprotein capture and release was assessed by western blot (Supplementary Figs. 2-4) . The released glycopeptides were analyzed by reversed-phase nanoflow liquid chromatography coupled to a Thermo LTQ-Orbitrap XL mass spectrometer.
In traditional proteomics approaches, tandem MS is performed on the most abundant species in the full-scan mass spectra to the exclusion of lower-abundance species (Fig. 2b) . In contrast, IsoTaG enables mass-independent, targeted glycoproteomics (Fig. 2c) . Glycopeptides displaying the isotopic signature are computationally detected by the pattern-searching algorithm 28 , which produces an inclusion list of m/z values and retention times (±2-min window) for ions bearing isotopically recoded envelopes. We then performed an inclusion list-directed tandem MS run, where we typically observed a <0.5-min shift in retention time. Femtomole quantities of tagged proteins at a signal-to-noise ratio of 2.5:1 were detectable with the pattern-recognition algorithm 28 . Owing to the versatility of the algorithm 28 , species up to 12 kDa that have incorporated multiple tags are also directed to the inclusion list and have an equal chance of selection for tandem MS.
isotaG improves selection of low-abundance glycopeptides
To assess the advantage of IsoTaG over traditional data-dependent acquisition, we performed a series of back-to-back runs with and without the inclusion list and evaluated the total number of isotopically recoded species selected for tandem MS. A fourfold improvement in tagged glycopeptides selected for tandem MS was observed across all fractions and glycan types ( Supplementary  Fig. 5 ). In total, over 1,500 isotopically recoded species were selected for tandem MS from Ac 4 GalNAz-labeled and Ac 4 ManNAz-labeled Jurkat cell lysates using the inclusion list, as compared to 385 without. This selection factor indicates that IsoTaG effectively targets low-abundance species and mitigates the need for extensive fractionation, mass spectrometer analysis time and computation time. To assess the rate of off-target labeling, we quantified the number of isotopically recoded species npg selected for tandem MS from the DMSO control samples. Using the same procedure, we found 52 isotopically recoded off-target species in the DMSO control (off-target rate = 3%).
We then repeated the enrichment procedure with PC-3 and MCF-7 cell lines. Because of our interest in identifying lowabundance glycopeptides, tandem MS was performed using collision-induced dissociation (CID) to achieve the highest sensitivity. Figure 2c illustrates the identification of an N-glycoprotein from Ac 4 GalNAz-labeled Jurkat lysates. Inclusion list-triggered tandem MS of an isotopically recoded precursor ion generated a tandem mass spectrum (MS2) for assignment of glycan structure from charged and neutral losses. Subsequent data-dependent CID of the three most intense ions in the MS2 spectrum generated MS3 spectra for glycopeptide amino acid sequence identification by database searching. In a typical MS duty cycle, we performed inclusion list-driven MS2 on the top three precursor ions, and the three most intense fragment ions in each MS2 spectrum were selected for MS3 analysis, for a total of nine events following MS1.
By virtue of their isotopically recoded mass envelopes, glycopeptides could be identified in a targeted, mass-independent manner (Fig. 3) . MS2 and MS3 spectra of isotopically recoded precursor ions were searched against the Swiss-Prot human proteome using the Sequest HT algorithm within Proteome Discoverer software. Unassigned spectra were then searched in an iterative fashion using the UniProtKB human proteome and Byonic, a program specialized for variable-modification searches. Glycans were assigned manually from the MS2 spectra, and glycan structures were inferred from the observed neutral or charged losses ( Supplementary  Fig. 6 ). Ambiguous glycan types (for example, GlcNAz vs. GalNAz) were inferred from the subcellular localization of the underlying peptide or the most likely glycan structure (for example, O10 and O11; Fig. 3b ). All assignments were validated for isotopic distribution, exact mass (mass error, ∆mass < 5 p.p.m.), charged or neutral loss of the glycan, and peptide fragment ions. None of the assigned glycopeptides was detected in the DMSO control samples. To assess reproducibility, we performed biological replicates of the enrichment procedure with the Jurkat cell line and found that approximately half of the glycopeptides were identified in all three replicates, and 78% were found in two of three replicates (Fig. 4a) . In aggregate, 32 N-and over 500 O-glycopeptides from 250 glycoproteins were identified, of which 220 peptides and 120 proteins were not previously known to be glycosylated.
mass spectrometry data analysis
The identified glycopeptides represent a range of proteins and glycan types. Sixteen N-glycan types were identified (N1-N16; Fig. 3a) , in which immature and high-mannose structures were more predominant than we expected (Fig. 3c) . In addition to the 32 fully characterized N-glycopeptides, we partially characterized 156 N-glycopeptide spectra (for example, the glycan was sequenced but not the underlying peptide npg fully identifiable N-glycopeptides mainly reflects difficult elucidation by MS (up to four SiaNAz glycans were observed in a single species, but the entire glycoform was unresolved) but may also be caused by hindered access of probe 1 or reduced ionization efficiency. Alternatively, metabolically labeled immature N-glycans may be more abundant than elaborated N-glycans in the samples evaluated, a hypothesis supported by previous observations using lectin chromatography 24 . To fully characterize the peptides carrying N-glycans, we performed the enrichment using conditioned medium from PC-3 cells metabolically labeled with Ac 4 GalNAz, Ac 4 ManNAz or DMSO. After trypsin digestion, we used PNGase F in 18 O-water to release only peptides with N-glycans and found 54 formerly N-glycosylated peptides at 1% false discovery rate. These samples represent one-ninth of the total fractions evaluated herein, indicating that N-glycoproteins are labeled and captured by our enrichment procedure. Unfortunately, we could no longer characterize the structures that occupied the glycosite using this established method 23 .
Identified O-glycan types corresponded to O-GlcNAc (O1), Tn (O2), STn (O5), Cores 1-4 (O3, O11, O4 and O10, respectively) and sialylated glycans (O6, O7, O8 and O9) (Fig. 3b) . The preponderance of O-GlcNAcylated peptides (Fig. 3d) reflects, at least in part, the efficiency of the GALE epimerase to biosynthesize UDP-GlcNAz from Ac 4 GalNAz 15 . Additionally, terminal glycans (for example, GlcNAz) may be easier to tag with probe 1. Nonetheless, O-GlcNAcylated proteins are highly abundant on the basis of other analyses 32 .
Fragmentation of the glycan occurs before fragmentation of the peptide backbone with CID, enabling the assignment of glycan structure-but not the underlying peptide-for several of the elaborated glycopeptides. Whereas electron-transfer dissociation (ETD) is an orthogonal fragmentation method for peptides bearing CID-labile PTMs 33 , we found that halogenated glycopeptides have low ETD fragmentation efficiency. The mucin-type O-glycans identified were predominantly various sialylation states of core 1 O-glycans from PC-3 and MCF-7 cell lines. Jurkat cells displayed highly heterogeneous O-glycopeptides owing to the knockdown of core 1 O-glycan elaboration via truncation of the COSMC chaperone 34 . Notably, core 1 O-glycans from Jurkat cells were still identified, as truncated COSMC maintains 2-5% activity of the full-length protein. The presence of core 1 glycoproteins in the conditioned medium from Jurkat cells was confirmed by lectin staining (Supplementary Fig. 7) .
Interestingly, unique subpopulations of glycopeptides were enriched with either GalNAz or ManNAz labeling (Fig. 4b) . The predicted subcellular localization of the identified glycoproteins reflected the prevalence of nuclear and cytoplasmic O-GlcNAzylated peptides identified (Fig. 4c) . Nonetheless, the identified glycoproteins were highly cell specific. Of the characterized npg glycoproteins, 60% were found exclusively in one of the three cell types, and 30% in two of the three cell types (Fig. 4d) .
We identified intact glycopeptides with multiple glycoforms (Supplementary Table 1 ). Elaborated glycopeptides possessed a high degree of glycoform variation, including peptides derived from the same protein (O94907) or from different proteins (for example, O94907 and Q14766). Up to five glycoforms were observed for a single peptide (P14314), and several peptides possessed four detected glycoforms (P02786, Q02818, Q12841, Q14242 and Q92854).
identification of peptide sequence polymorphisms
Approximately 60% of isotopically recoded species were assigned by database searching methods described above. The remaining 40% of tandem mass spectra of isotopically recoded species were unassigned from database searching alone. In some cases, spectral nonassignment was related to low signal-to-noise ratios of fragment ions or the presence of unidentified chemical modifications (for example, unexpected fragments and CuAAC-related off-target reactivity). In other cases, however, we suspected that failure to identify glycopeptides from database searching was due to the absence of a matching amino acid sequence in the protein database. To investigate this possibility, we collected an additional data set on Ac 4 ManNAz-labeled PC-3 cell lysates, with full-scan mass spectra and MS2 spectra acquired in the Orbitrap analyzer to obtain high-resolution measurement of both precursor and fragment ions. Targeted analysis of this data set revealed 21 glycopeptides carrying pSPs that were not present in the protein database (UniProtKB) and one pSP previously observed by genetic sequencing 35 . For example, a total of 15 isoforms were identified, representing four glycan types and six pSPs derived from prostateassociated microseminoprotein 36 (Fig. 5 and Supplementary  Fig. 8 ). Polymorphic peptides additionally carry glycoform variants (for example, P14314 and Q1L6U9; Supplementary Table 1); this is potentially related to variable levels of abundance or indicative of differential biosynthetic processing of the underlying peptide.
Identification of protein polymorphisms in cancer is an area of intense study on the genomic 37 and proteomic 38, 39 levels. Interestingly, all pSPs identified from PC-3 cells, a metastatic prostate cancer cell line, were mutations of alanine to serine or of proline to threonine. The selectivity of mutations observed in our data may be related to the glycan-dependent enrichment strategy. Alternatively, as aberrant glycosylation is a hallmark of cancer, particularly in metastasis 40 , an increase in O-glycosylation sites may play a significant role and is a subject for future investigation. discussion Unlike previous methods, which require cleavage or truncation of glycans for glycosite mapping, IsoTaG identifies fully elaborated glycopeptides, revealing the inherent structural details of npg the glycoproteome. Use of the IsoStamp algorithm increased selection of glycopeptide species for tandem MS by fourfold and facilitated mass-independent targeted database searching for high-confidence assignment. As described, the enrichment and recovery of metabolically labeled glycopeptides with probe 1, MS analysis and initial data analysis were all performed in 3 d. In our preliminary study we found that IsoTaG was highly reproducible using biological replicates from Jurkat lysates. With Jurkat, PC-3 and MCF-7 cell lines, 50% of identified glycoproteins and 60% of identified glycopeptides were novel, suggesting that many more glycoproteins, and particularly O-glycoproteins, remain to be discovered. Indeed, the assignment of a large number of novel O-glycopeptides further highlights the ability of IsoTaG to survey new classes of glycoproteins. A 3% off-target CuAAC rate was found with the Jurkat cell line, as quantified by the number of isotopically recoded species selected for tandem MS in labeled versus control samples. Protein glycosylation was also highly cell specific, as 60% of the identified glycoproteins were found exclusively in one of the three cell types (30% in two of three cell types). As less than 2% of proteins are expressed in a cell-specific manner 41 , analysis of glycoproteins may be an important source of tissue-specific diversity and disease biomarkers. Notably, any covalent labeling strategy may be integrated into the IsoTaG platform to achieve enrichment and targeted proteomics of low-abundance species. We have illustrated the generality of the platform by using two metabolically labeled glycans: Ac 4 GalNAz and Ac 4 ManNAz. Use of highly glycan-specific metabolic 17, 18 or enzymatic 42 labels may enable focused analysis of particular glycan types. Incorporation of the isotopic pattern via metabolic heavy-atom labeling is also a viable alternative 43 . An Orbitrap mass spectrometer was used in the present study; however, other types of mass spectrometers that can achieve high resolution (for example, quadrupole time-of-flight analyzers) can also be employed 28 . Recent advances in nested fragmentation techniques (such as higher-energy collisional dissociation with accurate mass-product-dependent ETD) show promise toward a targeted glycoproteomics approach and may be incorporated into an IsoTaG strategy 44, 45 .
IsoTaG represents the first proteome-scale platform in which the glycan structure and peptide can be identified for both intact N-and O-glycopeptides. Recognition of tagged glycopeptides by full-scan MS improved rates of selection and characterization, such that 60% of isotopically recoded species were characterized (glycan structure and peptide), including the identification of novel pSPs. These results point to a wealth of information in the proteome and glycome that are not covered in current databases. Given that on average 20% of spectra in a data set are assigned by database searching 46 , we suggest that a targeted isotopic recoding approach may be broadly useful for the future discovery of novel protein isoforms, including nontemplated PTMs and pSPs. 1-tert-butyl-1H-1,2,3 -triazol-4-yl)methyl]amino}methyl)-1H-1,2,3-triazol-1-yl]propanol (BTTP) was prepared according to the method of Wu and coworkers 49 . Tetraacetylated N-azidoacetyl galactosamine was prepared according to the method of Bertozzi and coworkers 50 . Tetraacetylated N-azidoacetyl mannosamine was prepared according to the method of Bertozzi and coworkers 51 . EDTA-free protease inhibitor cocktail was obtained from Roche Diagnostics (Version 11). Streptavidin-agarose beads were obtained from Thermo Scientific and washed with PBS before use. High-sensitivity streptavidin-HRP was obtained from Pierce (catalog number 21130). PNGase F was purchased from NEB (catalog number P0704S).
Cell culture. All cell lines were obtained from the American Type Culture Collection (ATCC) and maintained at 37 °C and 5% CO 2 in a water-saturated incubator. Jurkat and PC-3 cells were maintained in RPMI-1640 supplemented with 10% FBS and 1% penicillin/streptomycin. MCF-7 cells were maintained in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Cell lines were metabolically labeled between passages 4-7 (MCF-7), 6-10 (Jurkat), or 17-22 (PC-3) and visually inspected daily for the presence of mycoplasma.
Cell culture flasks were seeded with 100 µM of Ac 4 GalNAz, Ac 4 ManNAz, or vehicle control containing DMSO (3.0 µL). A suspension of cells (2 × 10 5 cells/mL) was added to the flask, and the flask was incubated for 48 h at 37 °C. Flasks containing adherent cells were aspirated, and the cells were washed with PBS. The contents of flasks containing suspension cells were transferred to centrifuge tubes, and the cells were pelleted (300g, 3 min). The medium was aspirated, and cell pellets were washed with PBS. Cells were resuspended in complete medium containing 100 µM glycan metabolite without FBS additive, and the cells were incubated an additional 48 h at 37 °C.
Medium (100 mL) was harvested and cleared by centrifugation (300g, 3 min). Clarified medium was spin concentrated (Amicon, 15-mL 10-kDa spin filter) to 1 mL. The concentrated residue was washed with PBS (three washes of 15 mL each: 3 × 15 mL) and transferred to an Eppendorf microcentrifuge tube as the "conditioned medium fraction. " Adherent cells were washed with PBS (1 × 10 mL) and trypsinized for 5 min at 37 °C. Cells were harvested, centrifuged (300g, 3 min), and washed with PBS. Suspension cells were pelleted by centrifugation (300g, 3 min) and washed with PBS. Cell pellets were resuspended in lysis buffer (2 mL: 10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5% Triton X-100, 1× protease inhibitors, 1 µM thiamet G), swelled for 5 min on ice, and broken by Dounce homogenization using a tight glass hand pestle (Wheaton, 30 strokes). Insoluble material was pelleted by centrifugation (3,700g, 10 min, 4 °C). The supernatant was collected as the "soluble fraction" and the pellet kept as the "insoluble fraction." The insoluble fraction was resuspended in 1% RapiGest/PBS and briefly probe sonicated. The conditioned medium and soluble fractions were adjusted to 1% RapiGest/PBS. nAture methods algorithm. Data acquisition was controlled using Xcalibur software (version 2.0.7, Thermo). The raw data are available upon request.
Data analysis. The raw data were processed using Proteome Discoverer 1.4 software and searched against the human-specific SwissProt-reviewed database downloaded 18 July 2014. Tandem MS data were screened for glycopeptide signifiers including isotopically recoded precursor ion in full-scan mass (i.e., MS1) spectra, and neutral or charged glycan losses in MS2 spectra. Selected MS2/MS3 spectra were documented and saved separately. Saved spectra were manually annotated for glycoform and peptide mass. Saved spectra were then searched iteratively using the Byonic search algorithm v2.0 as a node in Proteome Discoverer 1.4. Computational assignments of all spectra were validated by manual inspection for glycan and peptide fragments. High probability assignments were inspected for validity, and unassigned spectra were archived for further analysis. Unassigned spectra from the initial searches were sorted on the basis of glycan type derived from fragment ions observed in the MS2 spectra (for example, HexNAzBr 2 OH, elaborated O-glycan, or elaborated N-glycan) and searched with variable modification using a focused glycan database. Finally, spectra that remained low-confidence assignments were manually inspected for similarities to assigned spectra (i.e., characteristic peptide fragment ions) or searched against the UniProtKB database (downloaded 30 September 2014) with variable modification on the specific glycan structure. Mass spectrometry spectra are provided as Supplementary Data 1-4 and annotated as losses from the MS (n − 1) precursor mass as follows: glycan(number of glycan units) in reverse order of the observed losses. Glycans at separate sites are separated by a comma. The glycan annotations used are HexNAzBr2OH = C 15 
